Thu, Sep 18, 2014, 2:13 PM EDT - U.S. Markets close in 1 hr 47 mins

Recent

% | $
Quotes you view appear here for quick access.

Star Scientific, Inc. (CIGX) Message Board

  • bhp1rtp bhp1rtp Jan 19, 2013 2:48 PM Flag

    Big pharma and wipo patent

    I wonder if big pharma is waiting on this patent with the WIPO (WO2011119722) before they spend big money for Star or to partner with Star
    THEY WOULD NOT WANT TO SPEND BIG$ WITHOUT THE PATENT
    Today we are one steep closer with the report that was generated today by the WIPO

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Yeah Ive read the patent a bunch of times and i know what its about. I assume you are looking on the Documents tab. If so the recent update is not an update but just a status report generated on the date you run the report. Check the date today, it states 1/20. From what I can see, the last entry was September 2012 (9/25), when star received their international search report and it came back with some hurdles. Star is pretty good at ironing out patents, but there is prior art from what I can see, including one from yes, RJR. I dont know if star will or will not get the use patent, but I do know its vital to their success. Again, the manufacture patent is a good thing to have, but the Use patent protects using Abine to treat specific diseases.

      If you see something different, please post but I believe the status report is not an announcement of a milestone.

    • Here we go again. The same brilliant team is assembled as in the tobacco litigation. A big distraction that will take years to unravel to ensure JW can continue his sordid hijinks And it will end in nothing, like before. Am I surprised??? Connect the dots people. SCAM

    • I'm not a paptent attorney but have several patents. Having the original patent for the production of anatabine citrate protects the original against all other methods of production as of the date of the original filing. Finding another way to produce the product does not qualify for patent protection since the original is already filed and the patent office concurred in the validity. After something is deemed new and novel and approved as a patent I dont think the patent office would even consider and application. As I saidI am not a patent attorney but I don't think another apllication for the production of anatabine citrate has a chance of a snowball in hell of being approved by the Patent Office.

    • I agree. The patent to manufacture is great, and provides some protection, however if another process is developed to synthesize ana-bine, then all bets are off. To date, no other patents to manufacture have been submitted. I would love to know the opinion of Rock Creek experts if another manufacture process could be invented. Perhaps difficult to determine but would love to know all the same.

      The use patent is another story. Its important that Star get it.

      Im not familiar with the WIPO process, it seems to me that this report is just a status report, no? Or does this report mean that a milestone was crossed?

      • 1 Reply to rick3568
      • Read the description. This patent covers every use for anatabine that Star could come up with start at line 45.
        If Star gets this patent big pharma will need Star to add anatabine to any drug they want to add anatabine to
        here is just part of a long list of items listed in the patent
        In some embodiments the disorder is brain swelling or a neurodegenerative disease such as multiple sclerosis, Alzheimer's disease, or Parkinson's disease. In other embodiments the disorder is inflammation related to a kidney disease, nephritis, glomerulonephritis, dialysis, peritoneal dialysis, pericarditis, chronic prostatitis, vasculitis, gout, or pancreatitis

        The list is very long.
        Have fun reading it

 
STSI
0.5801-0.0519(-8.21%)Jun 3 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.